



**GLENMARK PHARMACEUTICALS LIMITED**

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026;  
 Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off. Western Express Highway, Andheri (E), Mumbai - 400099.  
 Phone No: +91 22 4018 9999 Fax No: +91 22 4018 9986; Website: www.glenmarkpharma.com; Email: complianceofficer@glenmarkpharma.com; CIN: L24299MH1977PLC019982

**STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH, 2024**


(₹ in Millions, unless otherwise stated)

Sr. No.	Particulars	Standalone					Consolidated				
		Quarter ended 31/03/2024 (Audited)	Quarter ended 31/12/2023 (Unaudited)	Quarter ended 31/03/2023 (Audited)	Year ended 31/03/2024 (Audited)	Year ended 31/03/2023 (Audited)	Quarter ended 31/03/2024 (Audited)	Quarter ended 31/12/2023 (Unaudited)	Quarter ended 31/03/2023 (Audited)	Year ended 31/03/2024 (Audited)	Year ended 31/03/2023 (Audited)
I	Revenue from operations										
	(a) Net sales	20,771.32	13,041.63	18,749.65	76,497.61	80,196.66	30,160.07	24,602.90	29,583.66	116,354.56	114,319.38
	(b) Other operating income	710.91	609.33	640.83	2,413.58	2,009.96	469.45	464.12	421.47	1,776.41	1,512.97
	Total revenue from operations	21,482.23	13,650.96	19,390.48	78,911.19	82,206.62	30,629.52	25,067.02	30,005.13	118,130.97	115,832.35
II	Other income	7,862.70	2,588.15	2,329.65	11,680.24	9,859.39	7,371.65	454.10	(424.24)	8,399.94	2,889.01
III	Total income (I + II)	29,344.93	16,239.11	21,720.13	90,591.43	92,066.01	38,381.17	25,521.12	29,580.89	126,530.91	118,721.36
IV	Expenses										
	(a) Cost of materials consumed	6,854.51	7,011.74	7,770.88	29,904.11	30,358.76	7,543.09	6,575.05	6,080.27	31,578.22	31,857.27
	(b) Purchases of stock-in-trade	816.58	777.22	860.54	3,227.82	3,911.92	2,108.04	4,131.05	2,433.13	14,511.70	13,124.66
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(21.20)	(839.43)	(64.33)	(1,030.70)	(313.65)	304.15	(383.52)	1,042.89	(1,956.22)	(2,406.57)
	(d) Employee benefits expense	3,377.45	3,795.60	3,061.20	14,347.75	13,465.08	7,009.55	7,530.37	6,137.65	28,681.43	26,007.76
	(e) Finance costs	833.85	736.04	588.60	2,771.10	2,068.16	1,485.59	1,343.44	1,091.37	5,159.89	3,490.36
	(f) Depreciation, amortisation and impairment expense	524.01	511.62	467.29	2,021.62	1,841.48	1,513.37	1,470.75	1,350.16	5,819.06	5,691.74
	(g) Other expenses	5,480.41	4,748.51	5,585.48	20,045.58	20,056.84	8,821.26	9,300.55	8,332.08	33,362.53	30,899.18
	Total expenses (IV)	17,865.61	16,741.30	18,269.66	71,287.28	71,388.59	28,585.05	29,967.89	28,467.55	117,156.41	108,664.40
V	Profit/(loss) before exceptional items and tax (III - IV)	11,479.32	(502.19)	3,450.47	19,304.15	20,677.42	9,776.12	(4,446.57)	1,113.34	9,374.50	10,056.96
VI	Exceptional items (gain)/ loss (Refer note 5)	(51,469.13)	252.83	6,583.72	(50,703.31)	4,958.68	4,467.85	767.24	7,997.32	9,009.55	7,658.54
VII	Profit/(loss) before tax from continuing operations (V - VI)	62,948.45	(755.02)	(3,133.25)	70,047.46	15,718.74	5,308.28	(5,213.81)	(6,883.96)	364.95	2,398.42
VIII	Tax expense :										
	Current tax	10,553.79	(531.67)	846.54	10,499.92	3,869.31	10,581.74	(220.74)	1,198.22	11,155.52	4,162.90
	Deferred tax	6,257.71	(19.26)	(2,605.10)	7,834.63	(238.26)	7,112.99	(497.27)	(2,587.26)	7,517.93	(868.87)
IX	Profit/(loss) after tax for the period from continuing operations (VII - VIII)	46,136.95	(204.09)	(1,374.69)	51,672.91	12,087.69	(12,386.45)	(4,495.80)	(5,494.94)	(18,308.50)	(895.61)
X	Profit/(loss) for the period from continuing operations attributable to:										
	- Non-controlling interests	-	-	-	-	-	40.10	205.59	251.66	681.46	801.55
	- Owners of the Company	46,136.95	(204.09)	(1,374.69)	51,672.91	12,087.69	(12,426.55)	(4,701.39)	(5,746.60)	(18,989.96)	(1,697.15)
XI	Profit/(loss) before tax from discontinued operations (Refer note 6)	-	-	-	-	-	310.80	1,606.83	1,976.30	5,326.92	5,286.09
XII	Tax expense of discontinued operations :										
	Current tax	-	-	-	-	-	72.73	388.61	473.11	1,284.32	1,506.11
	Deferred tax	-	-	-	-	-	(6.69)	30.57	39.62	69.32	110.37
XIII	Profit/(loss) after tax for the period from discontinued operations (XI - XII)	-	-	-	-	-	243.76	1,187.65	1,463.57	3,973.28	4,669.61
XIV	Profit/(loss) for the period from discontinued operations attributable to:										
	- Non-controlling interests	-	-	-	-	-	-	-	-	-	-
	- Owners of the Company	-	-	-	-	-	243.76	1,187.65	1,463.57	3,973.28	4,669.61
XV	Profit/(loss) after tax for the period from continuing and discontinued operations (IX + XIII)	-	-	-	-	-	(12,142.69)	(3,308.15)	(4,031.37)	(14,335.22)	(3,774.00)
XVI	Profit/(loss) for the period from continuing and discontinued operations attributable to:										
	- Non-controlling interests	-	-	-	-	-	40.10	205.59	251.66	681.46	801.55
	- Owners of the Company	46,136.95	(204.09)	(1,374.69)	51,672.91	12,087.69	(12,182.79)	(3,513.74)	(4,283.03)	(15,016.68)	(2,972.45)
XVII	Other comprehensive income from continuing operations	-	-	-	-	-	-	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss	(9.74)	9.40	(41.64)	(73.14)	9.71	9.03	9.03	105.14	(163.06)	165.09
	(ii) Income tax relating to items that will not be reclassified to profit or loss	9.44	(15.96)	14.55	25.56	(3.39)	26.65	(15.97)	(5.95)	42.75	(23.20)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	846.57	80.95	444.17	(399.03)	1,849.80
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	(20.13)	8.84	34.68	(79.97)	(451.52)
XVIII	Total comprehensive income from continuing operations for the period/year	46,136.65	(210.65)	(1,401.78)	51,625.33	12,094.01	(11,627.47)	(4,412.95)	(4,916.90)	(18,907.81)	644.56
XIX	Other comprehensive income from discontinued operations for the period/year	-	-	-	-	-	(0.19)	(35.42)	3.75	(56.23)	(2.90)
XX	Total comprehensive income from discontinued operations for the period/year (XVII + XIX)	(0.30)	(6.56)	(27.09)	(47.58)	6.32	243.57	1,152.23	1,467.32	3,917.05	4,666.71
XXI	Other comprehensive income for the period/year from continuing and discontinued operation (XVIII + XX)	46,136.65	(210.65)	(1,401.78)	51,625.33	12,094.01	(11,383.89)	(3,260.72)	(3,449.58)	(14,990.76)	5,317.27
XXII	Total comprehensive income for the period/year from continuing and discontinued operation (XVIII + XX)	46,136.65	(210.65)	(1,401.78)	51,625.33	12,094.01	(11,383.89)	(3,260.72)	(3,449.58)	(14,990.76)	5,317.27
XXIII	Total comprehensive income attributable to:										
	- Non-controlling interests	-	-	-	-	-	40.22	199.32	252.29	672.00	800.83
	- Owners of the Company	46,136.65	(210.65)	(1,401.78)	51,625.33	12,094.01	(11,424.11)	(3,460.04)	(3,701.87)	(15,662.76)	4,510.44
XXIV	Paid up Equity Share Capital, Equity Shares of ₹ 1/- each	282.19	282.17	282.17	282.19	282.17	282.19	282.17	282.17	282.19	282.17
XXV	Other equity (other than revaluation reserve)	-	-	-	229,424.01	178,492.46	-	-	-	78,197.08	94,457.06
XXVI	Earning per share for continuing operations (EPS) (not annualised except for the year ended 31 March)										
	Basic (in Rupees)	-	-	-	-	-	(44.04)	(16.66)	(20.37)	(67.30)	(6.01)
	Diluted (in Rupees)	-	-	-	-	-	(44.04)	(16.66)	(20.37)	(67.30)	(6.01)
XXVII	Earning per share for discontinued operations (EPS) (not annualised except for the year ended 31 March)										
	Basic (in Rupees)	-	-	-	-	-	0.86	4.21	5.19	14.08	16.54
	Diluted (in Rupees)	-	-	-	-	-	0.86	4.21	5.19	14.08	16.54
XXVIII	Earning per share for continuing and discontinued operations (EPS) (not annualised except for the year ended 31 March)										
	Basic (in Rupees)	163.50	(0.72)	(4.87)	183.13	42.84	(43.17)	(12.45)	(15.18)	(53.22)	10.53
	Diluted (in Rupees)	163.50	(0.72)	(4.87)	183.13	42.84	(43.17)	(12.45)	(15.18)	(53.22)	10.53

**Glenmark Pharmaceuticals Limited**  
**Statement of Assets and Liabilities**  
 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	Standalone		Consolidated	
	As at 31/03/2024 Audited	As at 31/03/2023 Audited	As at 31/03/2024 Audited	As at 31/03/2023 Audited
<b>ASSETS</b>				
Non current assets				
Property, plant and equipment	14,970.05	14,353.33	29,190.77	29,127.06
Capital work-in-progress	1,754.95	1,590.71	4,193.24	10,658.24
Right of Use Asset	415.73	533.33	1,990.76	2,165.67
Goodwill	-	-	673.59	736.19
Other intangible assets	2,176.67	2,572.78	10,246.50	22,188.67
Intangible assets under development	221.70	132.66	2,425.56	1,238.15
Financial assets				
(i) Investments	129,647.91	103,327.10	7,896.64	445.73
(ii) Loans	75,056.60	68,740.68	-	-
(iii) Other financial assets	444.59	226.34	698.83	316.80
Deferred tax assets (net)	1,658.47	9,467.54	10,497.22	18,059.13
Other non-current assets	982.53	1,049.96	1,492.31	1,525.85
Total non-current assets	227,329.20	201,994.43	69,305.42	86,461.49
Current assets				
Inventories	11,426.86	10,902.14	25,130.51	23,736.20
Financial assets				
(i) Investments	-	-	-	-
(ii) Trade receivables	24,844.74	25,056.59	18,584.12	36,651.69
(iii) Cash and cash equivalents	1,279.64	926.96	11,592.03	11,592.03
(iv) Bank balance other than cash and cash equivalents	11.86	10.96	11.86	10.96
(v) Other financial assets	1,305.59	876.36	1,735.97	1,299.97
Current tax assets	-	-	-	-
Other current assets	7,946.05	6,078.76	12,235.66	10,945.52
Total current assets	46,814.74	43,851.77	74,280.82	84,236.37
Assets classified as held for sale	-	13.04	-	23,018.90
Total assets	274,143.94	245,859.24	143,586.24	193,716.76
<b>EQUITY AND LIABILITIES</b>				
Equity				
Equity share capital	282.19	282.17	282.19	282.17
Other equity	229,424.01	178,492.46	78,197.08	94,457.06
Equity attributable to owners' of Glenmark Pharmaceuticals Limited	229,706.20	178,774.63	78,479.27	94,739.23
Non-controlling interests	-	-	(3.80)	3,653.36
Liabilities				
Non-current liabilities				
Financial liabilities				
(i) Borrowings	-	26,608.18	-	38,521.38
(ii) Lease liabilities	224.47	332.90	1,516.91	1,771.22
(iii) Other financial liabilities	1,319.39	3,725.80	5,388.28	3,962.58
Deferred tax liabilities (net)	-	-	2.80	5.14
Other non-current liabilities	-	-	16.91	13.29
Total non-current liabilities	1,543.86	30,666.88	6,924.90	44,273.61
Current liabilities				
Financial liabilities				
(i) Borrowings	6,572.36	4,955.82	9,905.96	4,955.82
(ii) Lease liabilities	276.10	315.25	886.43	830.39
(iii) Trade payables	-	-	-	-
- Total outstanding dues of Micro enterprises and Small enterprises	173.32	547.83	173.32	547.83
- Total outstanding dues of other than Micro enterprises and Small enterprises	26,830.50	20,383.50	25,185.93	19,456.43
(iv) Other financial liabilities	4,749.97	8,142.29	10,269.84	12,115.59
Other current liabilities	744.20	447.61	2,443.63	1,6





**GLENMARK PHARMACEUTICALS LIMITED**

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026;  
Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off. Western Express Highway, Andheri (E), Mumbai - 400099.  
Phone No: +91 22 4018 9999 Fax No.: +91 22 4018 9986; Website: www.glenmarkpharma.com; Email: complianceofficer@glenmarkpharma.com; CIN: L24299MH1977PLC019982

**STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH, 2024**

(₹ in Millions, unless otherwise stated)

Sr. No.	Particulars	Standalone					Consolidated				
		Quarter ended 31/03/2024 (Audited)	Quarter ended 31/12/2023 (Unaudited)	Quarter ended 31/03/2023 (Audited)	Year ended 31/03/2024 (Audited)	Year ended 31/03/2023 (Audited)	Quarter ended 31/03/2024 (Audited)	Quarter ended 31/12/2023 (Unaudited)	Quarter ended 31/03/2023 (Audited)	Year ended 31/03/2024 (Audited)	Year ended 31/03/2023 (Audited)
I	Revenue from operations										
	(a) Net sales	20,771.32	13,041.63	18,749.65	76,497.61	80,196.66	30,160.07	24,602.90	29,583.66	116,354.56	114,319.38
	(b) Other operating income	710.91	609.33	640.83	2,413.58	2,009.96	469.45	464.12	421.47	1,776.41	1,512.97
	Total revenue from operations	21,482.23	13,650.96	19,390.48	78,911.19	82,206.62	30,629.52	25,067.02	30,005.13	118,130.97	115,832.35
II	Other income	7,862.70	2,588.15	2,329.65	11,680.24	9,859.39	7,731.65	454.10	(424.24)	8,399.94	2,889.01
III	Total income (I + II)	29,344.93	16,239.11	21,720.13	90,591.43	92,066.01	38,361.17	25,521.12	29,580.89	126,530.91	118,721.36
IV	Expenses										
	(a) Cost of materials consumed	6,854.51	7,011.74	7,770.88	29,904.11	30,358.76	7,543.09	6,575.05	8,080.27	31,578.22	31,857.27
	(b) Purchases of stock-in-trade	816.58	777.22	860.54	3,227.82	3,911.92	2,108.04	4,131.05	2,433.13	14,511.70	13,124.66
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(21.20)	(839.43)	(64.33)	(1,030.70)	(313.65)	304.15	(383.52)	1,042.89	(1,956.22)	(2,406.57)
	(d) Employee benefits expense	3,377.45	3,795.60	3,061.20	14,347.75	13,465.08	7,009.55	7,530.37	6,137.65	28,681.43	26,007.76
	(e) Finance costs	833.85	736.04	588.60	2,771.10	2,068.16	1,485.59	1,343.44	1,091.37	5,159.69	3,490.36
	(f) Depreciation, amortisation and impairment expense	524.01	511.62	467.29	2,021.62	1,841.48	1,513.37	1,470.75	1,350.16	5,819.06	5,691.74
	(g) Other expenses	5,480.41	4,748.51	5,585.48	20,045.58	20,056.84	8,621.26	9,300.55	8,332.08	33,362.53	30,899.18
	Total expenses (IV)	17,865.51	16,741.30	18,289.66	71,287.28	71,388.59	28,585.05	29,987.69	28,467.55	117,195.41	108,664.40
V	Profit/(loss) before exceptional items and tax (III - IV)	11,479.32	(602.19)	3,450.47	19,304.15	20,677.42	9,776.12	(4,466.57)	1,113.34	9,374.50	10,056.96
VI	Exceptional items (gain)/ loss (Refer note 5)	(51,469.13)	252.83	6,583.72	(50,703.31)	4,958.68	767.24	7,997.32	(6,883.98)	9,009.55	7,658.54
VII	Profit/(loss) before tax from continuing operations (V - VI)	62,948.45	(755.02)	(3,133.25)	70,007.46	15,718.74	5,308.28	(5,213.81)	(5,770.64)	18,384.05	2,398.42
VIII	Tax expense :										
	Current tax	10,553.79	(531.67)	846.54	10,499.92	3,869.31	10,581.74	(220.74)	1,198.22	11,555.52	4,162.90
	Deferred tax	6,257.71	(19.26)	(2,605.10)	7,834.63	(238.26)	(497.27)	(2,587.26)	(2,587.26)	7,517.93	(868.87)
IX	Profit/(loss) after tax for the period from continuing operations (VII - VIII)	46,136.95	(204.09)	(1,374.69)	51,672.91	12,087.69	(12,386.45)	(4,495.80)	(5,494.94)	(18,308.50)	(895.61)
X	Profit/(loss) for the period from continuing operations attributable to:										
	- Non-controlling interests	-	-	-	-	-	40.10	205.59	251.66	681.46	801.55
	- Owners of the Company	46,136.95	(204.09)	(1,374.69)	51,672.91	12,087.69	(12,426.55)	(4,701.39)	(5,746.60)	(18,989.96)	(1,697.15)
XI	Profit/(loss) before tax from discontinued operations (Refer note 6)	-	-	-	-	-	310.80	1,606.83	1,976.30	5,326.92	6,286.09
XII	Tax expense of discontinued operations :										
	Current tax	-	-	-	-	-	72.73	388.61	473.11	1,284.32	1,506.11
	Deferred tax	-	-	-	-	-	(5.69)	30.87	39.82	89.32	110.37
XIII	Profit/(loss) after tax for the period from discontinued operations (XI - XII)	-	-	-	-	-	243.76	1,187.65	1,463.57	3,973.28	4,669.61
XIV	Profit/(loss) for the period from discontinued operations attributable to:										
	- Non-controlling interests	-	-	-	-	-	-	-	-	-	-
	- Owners of the Company	-	-	-	-	-	-	-	-	-	-
XV	Profit/(loss) after tax for the period from continuing and discontinued operations (IX + XIII)	-	-	-	-	-	243.76	1,187.65	1,463.57	3,973.28	4,669.61
XVI	Profit/(loss) for the period from continuing and discontinued operations attributable to:										
	- Non-controlling interests	-	-	-	-	-	40.10	205.59	251.66	681.46	801.55
	- Owners of the Company	46,136.95	(204.09)	(1,374.69)	51,672.91	12,087.69	(12,182.79)	(3,513.74)	(4,283.03)	(15,016.68)	2,972.45
XVII	Other comprehensive income from continuing operations										
	A (i) Items that will not be reclassified to profit or loss	(9.74)	9.40	(41.64)	(73.14)	9.71	(94.10)	9.03	105.14	(163.06)	165.09
	(ii) Income tax relating to items that will not be reclassified to profit or loss	9.44	(15.96)	14.55	25.56	(3.39)	26.65	(15.97)	(5.95)	42.75	(23.20)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	846.57	80.95	444.17	(399.03)	1,849.80
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	(20.13)	8.84	34.68	(79.97)	(451.52)
XVIII	Total comprehensive income from continuing operations for the period/year	46,136.65	(210.65)	(1,401.78)	51,625.33	12,094.01	(11,627.47)	(4,412.95)	(4,916.90)	(18,907.81)	(644.56)
XIX	Other comprehensive income from discontinued operations for the period/year	-	-	-	-	-	(0.19)	(35.42)	3.75	(56.23)	(2.90)
XX	Total comprehensive income from discontinued operations for the period/year (XIII + XIX)	-	-	-	-	-	243.57	1,152.23	1,467.32	3,917.05	4,666.71
XXI	Other comprehensive income for the period/year from continuing and discontinued operation (XVIII + XIX)	(0.30)	(6.56)	(27.09)	(47.58)	6.32	758.79	47.43	581.79	(655.53)	1,537.27
XXII	Total comprehensive income for the period/year from continuing and discontinued operation (XVIII + XX)	46,136.65	(210.65)	(1,401.78)	51,625.33	12,094.01	(11,383.89)	(3,260.72)	(3,449.58)	(14,990.76)	5,311.27
XXIII	Total comprehensive income attributable to:										
	- Non-controlling interests	-	-	-	-	-	40.22	199.32	252.29	672.00	800.83
	- Owners of the Company	46,136.65	(210.65)	(1,401.78)	51,625.33	12,094.01	(11,424.11)	(3,460.04)	(3,701.87)	(15,662.76)	4,510.44
XXIV	Paid up Equity Share Capital, Equity Shares of ₹ 1/- each	282.19	282.17	282.17	282.19	282.17	282.19	282.17	282.17	282.19	282.17
XXV	Other equity (other than revaluation reserve)	-	-	-	-	-	-	-	-	-	-
XXVI	Earning per share for continuing operations (EPS) (not annualised except for the year ended 31 March)										
	Basic (in Rupees)	-	-	-	-	-	(44.04)	(16.66)	(20.37)	(67.30)	(6.01)
	Diluted (in Rupees)	-	-	-	-	-	(44.04)	(16.66)	(20.37)	(67.30)	(6.01)
XXVII	Earning per share for discontinued operations (EPS) (not annualised except for the year ended 31 March)										
	Basic (in Rupees)	-	-	-	-	-	0.86	4.21	5.19	14.08	16.54
	Diluted (in Rupees)	-	-	-	-	-	0.86	4.21	5.19	14.08	16.54
XXVIII	Earning per share for continuing and discontinued operations (EPS) (not annualised except for the year ended 31 March)										
	Basic (in Rupees)	163.50	(0.72)	(4.87)	183.13	42.84	(43.17)	(12.45)	(15.18)	(53.22)	10.53
	Diluted (in Rupees)	163.50	(0.72)	(4.87)	183.12	42.84	(43.17)	(12.45)	(15.18)	(53.22)	10.53

**Glenmark Pharmaceuticals Limited  
Statement of Assets and Liabilities**  
(All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	Standalone		Consolidated	
	As at 31/03/2024 Audited	As at 31/03/2023 Audited	As at 31/03/2024 Audited	As at 31/03/2023 Audited
<b>ASSETS</b>				
Non current assets				
Property, plant and equipment	14,970.05	14,353.33	29,190.77	29,127.06
Capital work-in-progress	1,754.95	1,590.71	4,193.24	10,658.24
Right of Use Asset	415.73	533.33	1,990.76	2,165.67
Goodwill	-	-	673.59	736.19
Other intangible assets	2,176.67	2,572.78	10,246.50	22,188.67
Intangible assets under development	221.70	132.66	2,425.56	1,238.15
Financial assets				
(i) Investments	129,647.91	103,327.10	7,896.64	445.73
(ii) Loans	75,056.60	68,740.68	-	-
(iii) Other financial assets	444.59	226.34	698.83	316.80
Deferred tax assets (net)	1,658.47	9,467.54	10,497.22	18,059.13
Other non-current assets	982.53	1,049.96	1,492.31	1,525.85
Total non-current assets	227,329.20	201,994.43	69,305.42	86,461.49
Current assets				
Inventories	11,428.86	10,902.14	25,130.51	23,736.20
Financial assets				
(i) Investments	-	-	-	-
(ii) Trade receivables	24,844.74	25,056.59	18,584.12	36,651.69
(iii) Cash and cash equivalents	1,279.64	926.96	16,582.70	11,992.03
(iv) Bank balance other than cash and cash equivalents	11.86	10.96	11.86	10.96
(v) Other financial assets	1,305.59	876.36	1,735.97	1,299.97
Current tax assets	7,946.05	6,078.76	12,235.66	10,945.52
Other current assets	46,814.74	43,851.77	74,280.82	84,236.37
Assets classified as held for sale	-	13.04	-	23,018.90
Total current assets	274,143.94	245,859.24	143,586.24	193,716.76
<b>EQUITY AND LIABILITIES</b>				
Equity				
Equity share capital	282.19	282.17	282.19	282.17
Other equity	229,424.01	178,492.46	78,197.08	94,457.06
Equity attributable to owners' of Glenmark Pharmaceuticals Limited	229,706.20	178,774.63	78,479.27	94,739.23
Non-controlling interests	-	-	(3.80)	3,653.36
Liabilities				
Non-current liabilities				
Financial liabilities				
(i) Borrowings	-	26,608.18	-	38,521.38
(ii) Lease liabilities	224.47	332.90	1,516.91	1,771.22
(iii) Other financial liabilities	1,319.39	3,725.80	5,388.28	3,962.58
Deferred tax liabilities (net)	-	-	2.80	5.14
Other non-current liabilities	-	-	16.91	13.29
Total non-current liabilities	1,543.86	30,668.88	6,924.90	44,273.61
Current liabilities				
Financial liabilities				
(i) Borrowings	6,572.36	4,955.82	9,905.96	4,955.82
(ii) Lease liabilities	276.10	315.25	886.43	830.39
(iii) Trade payables	-	-	-	-
- Total outstanding dues of Micro enterprises and Small enterprises	173.32	547.83	173.32	547.83
- Total outstanding dues of other than Micro enterprises and Small enterprises	26,830.50	20,383.50	25,185.93	19,456.43
(iv) Other financial liabilities	4,749.97	8,142.29	10,269.84	12,115.59
Other current liabilities	744.20	447.81	2,443.63	1,651.29
Provisions	1,150.34	970.10	6,411.24	4,920.09
Current tax liabilities (net)	2,397.09	655.13	2,909.52	984.98
Total current liabilities	42,893.88	36,417.73	58,185.87	45,462.42
Total liabilities	44,437.74			